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jointly bring the radiation community closer to that goal:  (1) joint 
evidence-based summaries of late effects scientific evidence (e.g. 
QUANTEC 2010 and pediatric QUANTEC, in progress) to reach a com-
mon standard of terminology across the radiation research disciplines, 
including, radiation oncology, physics, radiobiology, epidemiology, 
biostatistics etc.; (2) reach international consensus about standards 
for  real-time, prospective data registration of patients treated for 
cancer now, by including radiation dose and chemotherapy characte-
ristics , short-term and long-term health outcomes, and set-up such 
registries where feasible. Since such registries cannot, by definition, 
answer questions about long-term  effects, it is essential that we 
strengthen the retrospective study arena as well, by (3) including 
added measures (crude or detailed) of exposed organ volume and 
fractionation to existing retrospective study databases (e.g. de Bruin 
et al 2009) to enable international pooled analyses of joint dose-
volume effects for the very long-term late effects for which outcome 
data are already available. Finally, (4) novel  2D-to-3D dose recon-
struction methods to derive DVH-based doses recently proposed for 
Hodgkin lymphoma survivors (Ng et al 2010) should be validated and 
further developed for more general application in retrospective late 
effects studies to quantify the very long-term dose effect relation-
ships according to current standards of dose estimation. By working 
together more closely we can overcome current gaps between clinical 
radiation oncology and population-based studies.  
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Background: Long-term follow-up of women irradiated for breast 
cancer in both randomised trials and observational studies has re-
vealed that past breast cancer radiotherapy regimens have increased 
the risk of heart disease. Assessment of the relationship between 
heart radiation dose and heart disease requires detailed dosimetry. In 
women irradiated for breast cancer, measures of their cardiac dose 
can be combined with outcome information on subsequent heart 
disease to create dose-response relationships. These can then be used 
to predict the likely cardiac risk for women irradiated today.  
Methods: A large database of internationally used breast cancer 
radiotherapy techniques from the 1950s onwards was compiled using 
information from practising and retired radiation oncologists from 
several different countries, from radiotherapy textbooks, and from 
breast cancer radiotherapy protocols.  
Each breast cancer radiotherapy regimen was reconstructed using 
“virtual simulation” which involved the construction of a virtual 3-
dimensional patient representation using CT scan data from a repre-
sentative patient. Radiotherapy beams were designed and applied to 
this patient representation. Following this, the radiation beam and 
patient information were analysed using a CT planning system. For 
each regimen, dose volume histograms were generated and used to 
calculate a number of different measures of dose including mean dose 
and mean dose in equivalent 2 Gray fractions. Doses were estimated 
for the whole heart and for the three main coronary arteries. The 
main sources of variability associated with the dosimetry method were 
assessed.  
Cardiac doses were applied to women irradiated for breast cancer in 
two different studies. The first study included around 40,000 women 
irradiated in 76 randomised trials of radiotherapy in the Early Breast 
Cancer Trialists’ Collaborative Group Overview. In this study, mean 
heart dose was related to death from heart disease. The second study 
was a case control study including around 2,000 women. It investi-
gated incident ischaemic heart disease (myocardial infarction, coro-
nary revascularisation or death from ischaemic heart disease) in 
population-based registries in Denmark and Sweden. Mean heart 
radiation dose was related to risk of developing a major coronary 
event.  
Results: Radiation fields that were used to treat the internal mamma-
ry lymph nodes delivered the highest mean heart doses, particularly 
for left-sided irradiation. Of the cardiac structures considered, the 
left anterior descending coronary artery generally received the high-
est doses, due to its proximity to the left breast. Assessment of the 
effect of patient anatomy on heart dose showed that, although there 
was some interpatient variability in dose, there was greater dose 
variation between tumour laterality and between different regimens. 
In both the randomised and observational data, the risk of developing 
heart disease increased with increasing mean heart dose. In the 
randomised data, there was a 5% increase in heart death per Gray (SE 
1%, 2p<0.00001). In the population-based data, there was a 7% in-
crease in incident ischaemic heart disease per Gray (95% confidence 
interval 2-13%; 2p=0.0001).  
Conclusions: Virtual simulation and CT planning enable the measure-
ment of detailed estimates of cardiac radiation dose. 
The risk of developing heart disease increases with increasing mean 
heart dose, with no evidence of a threshold below which there is no 
risk. 
For women with no cardiac risk factors a mean heart dose of 1 Gray 
from breast cancer radiotherapy is likely to increase her absolute risk 
of an acute coronary event by around 0.5%, while for a mean heart 
dose of 2 Gray, the increase is likely to be around 1%.  Absolute risk 
increases will be larger for women who are already at increased 
cardiac risk prior to radiotherapy.   
 
 DEBATE: BRACHYTHERAPY IS THE OPTIMAL MODALI-
TY FOR DOSE ESCALATION IN H&N RADIO-THERAPY  
  
SP-0026   
Brachytherapy: een optimal tool for dose escalation of radiothera-
py in oropharyngeal cancer 
A. Al-Mamgani1, P.C. Levendag1 
1Erasmus Medical Center Rotterdam, Radiation Oncology, Rotterdam, 
The Netherlands  
 
Brachytherapy (BT) can be used for patients with early-stage head and 
neck cancer (HNC) from different subsites: oropharynx, nasopharynx, 
lip, check, and nasal cavity. 
Until recently, 5-year survival rates for locally-advanced HNC were 
reported to be 40% even with early multimodality approaches. Since 
1990s, the treatment of HNC has changed dramatically. Different 
strategies were implemented in order to improve loco-regional control 
(LRC) and overall survival (OS). However, the improvements in onco-
logic outcomes achieved by these efforts have come at the cost of 
increased toxicity and deterioration of QoL, mostly because of the 
increasing incidence of dysphagia and xerostomia. In order to reduce 
the incidence and severity of these complications and to improve QoL 
without jeopardizing outcomes, highly-conformal RT techniques are 
required.  
Given the increasing incidence of HPV-related oropharyngeal cancer 
(OPC) in the last decades, especially among young patients and the 
ongoing discussion in which group of patients dose escalation of RT is 
really necessary, we will limit our discussion on the potential role of 
dose escalation in patients with OPC.  
Is dose escalation really necessary in patients with OPC? 
In the last decades different new strategies have significantly im-
proved LRC and OS. The 5-year Kaplan-Meier estimate of LC was 78% 
for patients with locally-advanced OPC treated at our institution by 
accelerated scheme of chemo-IMRT. In these patients, feeding-tube 
dependence was needed in 65% and the incidence of grade ≥2 late 
toxicities was 44%. Despite the gains achieved, further improvement 
in oncologic outcomes and reduction of late toxicity is needed in all 
patients with OPC, in particular patients with locally-advanced and 
HPV-negative disease. As a result of using highly conformal RT tech-
niques (IMRT, BT, SRT) and the recent introduction of promising 
imaging techniques to predict the final outcome (DCE-MRI, DWI, and 
FDG-PET), dose escalation of RT become appealing. The implementa-
tion of different image-guided techniques, for instance cone-beam 
CT, will further facilitate such risk-adaptive approach to escalate the 
dose of radiotherapy, when needed.  
The current scheme of the Rotterdam Organ-Function Preservation 
Protocol consists of 46 Gy of (chemo)IMRT to all patients followed by a 
boost using BT or Cyberknife SRT for patients with T1-3N+ or IMRT-
boost for large tumors. The combination of 46 Gy of IMRT followed by 
a BT boost in 167 patients with OPC has resulted in excellent LC-rates 
(94% at 5 years) with low toxicity and satisfactory QoL scores. Only 
26% patients needed tube feeding. Grade ≥2 late xerostomia and 
dysphagia were seen in only 11 % and 8%, respectively. Besides T-
stage, the incidence of LRC was also significantly correlated with HPV-
status (p=0.05) and boost technique (BT, Cyberknife vs. IMRT, 
p<0.001) in our patients.  
Improvements of LRC-rates in high-risk OPC might be achieved by 
escalating the dose of RT to the GTV. Raktoe et al (2012) showed that 
70% of all LFs after RT for OPC were seen in the GTV, suggesting 
radioresistance in these tumor parts and might advocate for escalating 
the dose to the GTV.  
Our group is almost ready to launch a risk-adaptive dose escalation 
protocol for patients with OPC. DWI will be performed at baseline and 
after 40 Gy, in order to predict response on RT. Patients with poor 
response (ADC increase of <25%, compared to baseline threshold) 
would be the target for such dose escalation protocol. According to 
our protocol, OPC-patients receive 22 Gy of PDR-BT. In case of poor 
response to the initial treatment, the dose of the PDR will be esca-
lated from to 30 Gy.  
